Glutathione

Glutathione may support a range of conditions where endogenous levels are depleted due to high oxidative stress, systemic inflammation, or immune dysregulation. In addition, it plays an independent role in liver detoxification by aiding the elimination of harmful substances.

Alzheimer’s Disease and Parkinson’s Disease

Cardiovascular Disease

Chronic Fatigue Syndrome

COPD and Asthma

Decreased Hyperpigmentation & Improved Overall Skin Health

Depression and anxiety disorders

Diabetes

Inflammatory Bowel Disease

Liver Disease/Liver Detoxification of Harmful Chemicals

Multiple Sclerosis

Neuropathy

Rheumatoid Arthritis

Schizophrenia/Bipolar Disorders

• Individuals with pre-existing kidney disease should avoid high dose glutathione.
• Avoid in pregnant or breastfeeding individuals due to a lack of safety data.
• Excessive glutathione supplementation may impair immune signaling.
• Glutathione may exert a limited effect in patients already on a medication regimen that harnesses anti-inflammatory pathways.

Glutathione functions primarily as a potent intracellular antioxidant, neutralizing free radicals and reactive oxygen species (ROS) through its sulfur-containing thiol group. By donating electrons, it helps stabilize these reactive molecules and prevent oxidative damage to cells. It also plays a key role in detoxification by binding to toxins, making them more water-soluble and easier for the body to excrete. Additionally, glutathione supports immune function by aiding in the activation and regulation of immune cells, contributing to a balanced immune response. It helps maintain cellular integrity by modulating oxidative stress, assisting in protein repair, and influencing inflammatory pathways—ultimately promoting overall cellular homeostasis.

IMPORTANT INFORMATION ABOUT COMPOUNDED MEDICATIONS

This medication has been compounded (custom-prepared) by a pharmacy. Compounded medications are specially prepared for individual patient needs based on a valid prescription and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. These statements have not been evaluated by the FDA.

This compounded preparation:

• Has not been approved by the FDA
• Has not undergone FDA review for safety, effectiveness, or quality
• Is prepared specifically for you based on your prescriber's order
• Individual outcomes may vary

Dosing is determined by the prescribing provider based on patient-specific factors. Always follow your healthcare provider's instructions. Compounded medications are not subject to FDA approval and lack the same safety and efficacy data as FDA-approved commercial medications. This medication should be prescribed and monitored by a licensed healthcare professional familiar with the condition being addressed and the specific applications of the medication.

Eshkevari, Ladan, et al. “Efficacy of addition of the anti-inflammatory, IV glutathione to standard ketamine IV therapy in major depressive disorder.” Psychiatry Research 337 (2024): 115949.

Bell CJM, Mehta M, Mirza L, Young AH, Beck K. Glutathione alterations in depression: a meta-analysis and systematic review of proton magnetic resonance spectroscopy studies. Psychopharmacology (Berl). 2024 Dec 21. doi: 10.1007/s00213-024-06735-1. Epub ahead of print. PMID:39708105.

Bounous, G., and J. Molson. “Competition for glutathione precursors between the immune system and the skeletal muscle: pathogenesis of chronic fatigue syndrome.” Medical hypotheses 53.4 (1999): 347-349.

Dean OM, van den Buuse M, Bush AI, Copolov DL, Ng F, Dodd S, Berk M. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. Curr Med Chem. 2009;16(23):2965-76. doi: 10.2174/092986709788803060. PMID: 19689277.

Fitzpatrick AM, Jones DP, Brown LA. Glutathione redox control of asthma: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2012 Jul 15;17(2):375-408. doi: 10.1089/ars.2011.4198. Epub 2012 Mar 9. PMID: 22304503; PMCID: PMC3353819.

Kaplowitz N. The importance and regulation of hepatic glutathione. Yale J Biol Med. 1981 Nov-Dec;54(6):497-502. PMID: 7342494; PMCID:PMC2596047.

Ueno, Yuki, et al. “Dietary glutathione protects rats from diabetic nephropathy and neuropathy.” The Journal of nutrition 132.5 (2002): 897-900.

Bravenboer B, Kappelle AC, Hamers FP, van Buren T, Erkelens DW, Gispen WH. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia. 1992 Sep;35(9):813-7. doi: 10.1007/BF00399926. PMID: 1397775.

Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicology. 1994 Fall;15